Cardiovascular disease is amongst the major causes of death worldwide. Patients suffering from chronic kidney disease have an even higher cardiovascular risk. Both, cardiovascular disease and chronic kidney disease are highly prevalent and are expected to increase even more due to the aging population and our unhealthy lifestyles.
Cardiovascular and chronic kidney diseases, as well as their joint presentation as “cardiorenal diseases” have an enormous socio-economic burden. This urges the need for an increased focus on the development of novel diagnostic and therapeutic strategies focussing on the cardiorenal patient.
AMICARE Development GmbH was founded in 2022 as a spin-off of the RWTH Aachen University and Maastricht University with the aim to close the gap between research and clinical translation in the area of cardiovascular, kidney and cardiorenal diseases. We are dedicated to contribute to a sustainable improvement of the cardiorenal patients’ quality of life.
Therefore, we support clinical studies according to the highest quality standards. We also invest in innovation and contribute to top quality research.
Clinical and pharmaceutical studies are essential for improving diagnosis and treatment of cardiovascular and chronic kidney disease. Thus, AMICARE Development GmbH supports clinical studies according to the highest quality standards.
For more information:
AMICARE Development GmbH also contributes to top quality research, with as main research topics the cardiovascular and chronic kidney disease patient, underlying disease mechanisms and therapeutic strategies.
In a close cooperation with academic partners at the RWTH Aachen University as well as Maastricht University, we educate PhD and medical students as well as master and bachelor students in the field of cardiorenal diseases.
We are also partnering in European research consortia with other academic as well as private partners.
AMICARE | December 12, 2022
Cardiorenal disease is highly prevalent but current diagnostic and therapeutic possibilities are insufficient. In contrast to a strong focus on cardiovascular disease, the patient with chronic kidney disease is often “overseen”. Nonetheless, patients with chronic kidney disease show a highly increased cardiovascular risk. Furthermore, the pathological mechanisms underlying this increased risk of cardiovascular disease in these patients are expected to be different from those in the general population. With our aim to increase the focus on the cardiorenal patient both on the level of research as well as on the level of clinical translation and clinical studies, the idea of AMICARE Development GmbH was born.
In partnerships with both academic as well as private partners, AMICARE Development GmbH will invest in innovation and clinical studies to drive forward clinical translation to the benefit of the cardiorenal patient.
We are looking forward to an interesting and productive journey.
Veranstaltungsort:
Erholungs-Gesellschaft Aachen 1837
Reihstr. 13, 52062 Aachen
Bitte senden Sie Ihre Anmeldung an:
Marlo Verket, mverket@amicare.dev
Prof. Dr. Dirk Müller-Wieland
CEO
Phone: +49 173 5342517
E-Mail: dmuellerwieland@amicare.dev
Address:
AMICARE Development GmbH
Campus-Boulevard 55
52074 Aachen
Germany
